BspQ I
BspQ I creates linearized, scarless templates from plasmid DNA suitable for use in in vitro transcription. As a type IIS restriction enzyme that cleaves DNA outside its recognition site, the use of BspQ I to linearize plasmid DNA ensures that the 3′ end of the in vitro transcription template does not contain extra base pairs from the restriction site.
BspQ I creates linearized, scarless templates from plasmid DNA suitable for in in vitro transcription. As a type IIS restriction enzyme that cleaves DNA outside its recognition site, the use of BspQ I to linearize plasmid DNA ensures that the 3′ end of the in vitro transcription template does not contain extra base pairs from the restriction site. This keeps the template poly(A) sequence intact and promotes successful translation after mRNA synthesis.
BspQ I, HQ (high quality) has been manufactured with stricter quality standards and is supplied in a higher concentration and volume. For more information on the differences between our RUO, HQ, and GMP grade enzymes, please see the table below.
Overview
Perfect for preparing scarless in-vitro transcription templates from plasmid DNA
- Cuts outside recognition site keeping the poly(A) tail sequence intact, which promotes successful translation downstream of the in vitro transcription
- Linearizes plasmid DNA in one hour
- Comes in an HQ version to support a smooth transition from RUO to GMP grade RNA manufacturing
More Information
Applications
Linearization of plasmid DNA for use as a template for in vitro transcription.
Source
Escherichia coli carrying the plasmid containing the gene for BspQ I.
Additional product information
Please see the product's Certificate of Analysis for information about storage conditions, product components, and technical specifications. Please see the Kit Components List to determine kit components. Certificates of Analysis and Kit Components Lists are located under the Documents tab.
High Quality (HQ) products
- High quality grade and consistency
- High volume for scale-up production
- More similar to GMP grade enzymes than research grade enzymes for a smooth transition to scale-up manufacturing
- A reliable option for process development
Takara Bio's High Quality (HQ) reagents are manufactured to a higher standard than research use reagents, without meeting all the requirements for GMP grade. The table and grade descriptions below detail the differences between these three categories of product grade.
Table 1. Comparison of Takara's research, HQ (high quality), and GMP grades. Quality features passed in each grade are indicated by a checkmark. HQ grade has nearly as many quality features as the GMP grade and significantly more quality features than the research grade.
| Research | Development | Manufacturing | ||
| Quality feature | Evaluation stage | Research grade | HQ grade | GMP grade |
| Exonuclease/Endonuclease free | Final formulation | |||
|
Purity testing
|
Final formulation | - | ||
| AOF: animal- and human-origin free | Final formulation | - | ||
| Raw materials | - | - | ||
| β-lactam free | Final formulation | - | ||
| Raw materials | - | - |
Table 2. Requirement compliance of Takara's RUO, HQ (high quality), and GMP grades.
| Research | Development | Manufacturing | |
| Evaluation stage | Research grade | HQ grade | GMP grade |
| Raw materials | ISO 9001:2015 | ISO 9001:2015 | PIC/S GMP |
| Manufacturing process | ISO 9001:2015 | ISO 9001:2015 | PIC/S GMP |
Research grade
Research grade reagents are manufactured to meet the quality standards of general research reagents.
HQ grade
HQ grade reagents are manufactured to many of the same quality standards as GMP grade reagents, but may not be manufactured in a GMP facility. HQ grade reagents are a good choice for researchers who need high quality reagents but do not need GMP grade reagents, such as non-clinical tests or process development.
GMP grade
GMP grade reagents are manufactured and quality controlled in accordance with the GMP guidelines of PIC/S (Pharmaceutical Inspection Agreement and Pharmaceutical Inspection Joint Scheme). GMP grade reagents may be suitable for manufacturing active pharmaceutical ingredients for clinical trials.
Speed up your vaccine development with innovative technologies
Vaccines have significantly decreased the burden of infectious diseases worldwide since the development of the first vaccine more than 200 years ago that led to the eradication of smallpox. In recent years, the spread of severe infections has highlighted the critical need for the rapid development of vaccines against previously unknown pathogens to deal with pandemics such as COVID-19.
Discover how Takara Bio can help speed up your vaccine-development process.
Learn moreTakara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2023 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.
